Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary medicinal product is substantial. |
Clinical Added Value
| minor |
ESMYA offers a minor improvement in actual benefit (IAB IV) compared to leuprorelin in terms of tolerability in the pre-operative treatment of moderate to severe symptoms in uterine fibroids in adult women of childbearing potential. |
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
MBr2fqjFTS8Jz4s5
